Delivering the right medicine, to the right patient, at the right time.

Clinigen is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines.

1. Culture: Develop and retain talented people

2020 Progress

  • 36 employees completed the Clinigen Management Academy training program
  • Launched online recruitment platform
  • Launched global wellbeing program

Performance Metrics

  • Employee engagement score: 7.5

2021 Objectives

  • Integrate culture and values across the Group
  • Implement a global HR system
  • Develop a strategic resourcing plan
  • Improve people management capabilities
2. Technology: Upgrade technology platform to drive organic growth

2020 Progress

  • Launch of Clinigen One ERP in UK and US
  • Growth of Cliniport (proprietary web-based operating system) enabling the Group to better interact with the customer
  • Clinigen Direct localised for four markets
  • UK drug shortages tracker launched
  • Relaunch of FDA-compliant Proleukin US website

Performance Metrics

  • Number of products available on Cliniport and Clinigen Direct: >2,600

2021 Objectives

  • Regionally based customer services
  • Enhanced online ordering platform for Managed Access and ‘on-demand’ businesses in Unlicensed Medicines and for Commercial Medicines
  • Enhanced UK online ordering platform for QPL and Aseptics businesses in Unlicensed Medicines
3. Customer: Expand and embed a global community of HCPS and opinion leaders

2020 Progress

  • Increase in number of MAPs and exclusive Global Access client supply agreements driving growth of Cliniport (proprietary web-based operating system) enabling the Group to better interact
    with the customer
  • Clinigen Direct localised for four markets
  • Relaunch of FDA-compliant Proleukin US website

Performance Metrics

2021 Objectives

  • Increase number of users and amount of activity through Cliniport and Clinigen Direct
  • Expand MSL and commercial capability in the US and the EU
  • Drive Key Opinion Leader (‘KOL’), hospital pharmacist and pharmacy group engagement across markets
4. Business: Expand portfolio of global, regional and licensed assets

2020 Progress

  • Exclusive global licensing and distribution agreement signed with PBL to commercialise Erwinase strengthens commercial offering in key markets
  • Collaboration with GC Pharma in Japan to submit new drug application for Hunterase
  • Exclusive agreement signed with Cheplapharm in Australia and New Zealand to distribute Etopophos and Vepesid
  • Internationalisation of Developed Products portfolio

Performance Metrics

2021 Objectives

  • Further conversion of UL2L pipeline
  • Further internationalisation of Developed Product portfolio
  • Continue to search for selective acquisitions and in-licensing agreements
  • Conversion of MAPs to regional licensing opportunities
5. Business: Become the 'go to' global leader in ethical access to unlicensed medicines

2020 Progress

  • EU entity established to maximise ‘on-demand’ opportunity
  • Increase in number of MAPs and exclusive Global Access client supply agreements
  • ‘Shortage Scramble Team’ established to maximise the opportunity in fulfilling global drug shortages
  • Rapidly flexed resources and efforts to react to COVID-19 related MAPs and Global Access ‘on-demand’ opportunity

Performance Metrics

2021 Objectives

  • Expand and deepen our client base in Managed Access
  • Grow and develop our portfolio of exclusive supply agreements
  • Drive growth in EU entity by developing portfolio, pricing and customer experience in key EU markets
  • Build RWD capability to provide a differentiated service to clients
  • Ensure smooth delivery of enhanced digital ordering platforms
6. Business: Extend global footprint into remaining key markets

2020 Progress

  • Exclusive global licensing and distribution agreement signed with Porton
    Biopharma to commercialise Erwinase strengthens commercial offering in key markets
  • Internationalisation of Developed Products portfolio

Performance Metrics

2021 Objectives

  • Further partnership agreements signed to expand geographical reach,
    particularly in the LATAM and the Middle East
  • Further expansion of commercial infrastructure in US and EU
7. Business: Link to Businesses to realise synergistic opportunities and increase pharmaceutical customer base

2020 Progress

  • Increase in the number of pharmaceutical and biotech companies working with all business operations
  • iQone supporting implementation and management of MAPs
  • Cross-divisional referrals driving pipeline and leading to new business wins

Performance Metrics

  • Number of pharmaceutical and biotech companies who have worked with all three business operations: 8 

2021 Objectives

  • Increase the number of pharmaceutical and biotech companies working with all business operations
  • Increase the number of companies working with at least two business operations
  • Increase the number of top 50 companies in which the Group has a relationship
  • Secure new business wins by moving a client or molecule through Clinigen’s lifecycle platform